Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
← catalyst calendarNCT05571059 · readout ≤ 165 d
Sponsored by Cumberland Pharmaceuticals (industry) · CPIX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
128estimated
Sites
19
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-31 | actual | When the study began enrolling |
| Primary completion | Jan 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-10-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Idiopathic Pulmonary Fibrosis
Interventions
- Drug: Ifetroban Sodium — also filed as ifetroban
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in Forced Vital Capacity (FVC) in mL
measured Baseline through 12 months
Publications
- PMID 35728047 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · CPIX's whole pipeline · Catalyst calendar · Every registered study · What changed